Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Avanos Medical (AVNS) Financials

Avanos Medical logo
$24.70 -0.05 (-0.18%)
Closing price 05/21/2026 03:59 PM Eastern
Extended Trading
$24.71 +0.02 (+0.06%)
As of 05/21/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Avanos Medical

Annual Income Statements for Avanos Medical

This table shows Avanos Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -426 40 79 58 -46 -29 6.30 51 -62 -392 -73
Consolidated Net Income / (Loss)		 -426 40 79 58 -46 -29 6.30 51 -62 -392 -73
Net Income / (Loss) Continuing Operations		 -101 -83 -32 -8.50 -46 -29 -31 22 -9.90 -386 -73
Total Pre-Tax Income 		-169 -139 -72 -18 -64 -63 -42 27 -7.90 -403 -66
Total Operating Income		 -136 -107 -43 0.50 -56 -49 -39 36 4.20 -396 -62
Total Gross Profit		 258 297 337 391 402 371 299 394 380 381 354
Total Revenue		 509 566 612 652 698 715 587 684 673 688 701
Operating Revenue		 509 566 612 652 698 715 587 684 673 688 701
Total Cost of Revenue		 251 269 275 261 295 344 288 290 294 307 347
Operating Cost of Revenue		 251 269 275 261 295 344 288 290 294 307 347
Total Operating Expenses		 394 404 380 390 458 419 338 359 376 778 416
Selling, General & Admin Expense		 350 346 322 340 399 333 285 327 335 319 316
Research & Development Expense		 28 38 38 42 38 35 31 29 27 26 23
Other Operating Expenses / (Income)		 16 20 20 8.20 21 52 22 3.00 13 -3.90 -0.40
Impairment Charge		 - - - - - - - 0.00 0.00 437 77
Total Other Income / (Expense), net		 -33 -32 -29 -19 -8.30 -14 -3.10 -8.80 -12 -7.10 -4.60
Interest Expense		 33 33 32 26 15 16 3.30 10 15 12 7.80
Interest & Investment Income		 0.30 0.60 2.50 7.80 6.70 1.20 0.20 1.20 2.90 5.10 3.20
Income Tax Expense		 -67 -56 -40 -9.60 -18 -34 -11 5.20 2.00 -17 6.70
Net Income / (Loss) Discontinued Operations		 -325 123 111 66 - - 37 29 -52 -5.80 0.00
Basic Earnings per Share		 ($9.15) $0.85 $1.69 $1.22 ($0.96) ($0.61) $0.13 $1.08 ($1.32) ($8.53) ($1.57)
Weighted Average Basic Shares Outstanding		 46.60M 46.60M 46.80M 47.20M 47.76M 47.97M 47.32M 46.60M 46.20M 46.00M 46.50M
Diluted Earnings per Share		 ($9.15) $0.85 $1.69 $1.22 ($0.96) ($0.61) $0.13 $1.07 ($1.32) ($8.53) ($1.57)
Weighted Average Diluted Shares Outstanding		 46.60M 46.60M 46.80M 47.20M 47.76M 47.97M 47.32M 46.60M 46.20M 46.00M 46.50M
Weighted Average Basic & Diluted Shares Outstanding		 46.60M 46.60M 46.80M 47.20M 47.76M 47.97M 47.32M 46.60M 46.20M 46.00M 46.50M

Quarterly Income Statements for Avanos Medical

This table shows Avanos Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.70 11 -0.90 1.80 4.30 -397 6.60 -77 -1.40 -1.30 5.10
Consolidated Net Income / (Loss)		 -3.70 11 -0.90 1.80 4.30 -397 6.60 -77 -1.40 -1.30 5.10
Net Income / (Loss) Continuing Operations		 -8.80 11 0.50 4.30 5.90 -397 6.60 -77 -1.40 -1.30 5.10
Total Pre-Tax Income 		-2.60 8.90 1.50 6.20 9.50 -421 9.70 -76 -1.20 1.20 7.60
Total Operating Income		 1.20 11 4.00 6.30 12 -419 10 -75 0.10 2.50 8.90
Total Gross Profit		 96 95 95 96 93 98 90 92 86 86 94
Total Revenue		 171 173 166 172 170 180 168 175 178 181 182
Operating Revenue		 171 173 166 172 170 180 168 175 178 181 182
Total Cost of Revenue		 76 78 71 76 78 82 78 83 92 95 88
Operating Cost of Revenue		 76 78 71 76 78 82 78 83 92 95 88
Total Operating Expenses		 94 84 91 89 81 517 80 167 86 84 85
Selling, General & Admin Expense		 79 75 84 81 74 80 76 84 78 79 78
Research & Development Expense		 6.10 6.80 7.00 6.30 7.20 5.70 5.40 5.80 6.00 6.10 5.20
Other Operating Expenses / (Income)		 9.50 2.50 0.20 2.10 -0.60 -5.60 -1.60 0.30 2.30 -1.40 2.40
Total Other Income / (Expense), net		 -3.80 -2.30 -2.50 -0.10 -2.50 -2.00 -0.60 -1.40 -1.30 -1.30 -1.30
Interest Expense		 4.70 3.30 3.10 3.10 3.20 2.80 2.10 2.00 1.80 1.90 1.50
Interest & Investment Income		 0.90 1.00 0.60 3.00 0.70 0.80 1.50 0.60 0.50 0.60 0.20
Income Tax Expense		 6.20 -2.10 1.00 1.90 3.60 -24 3.10 0.90 0.20 2.50 2.50
Basic Earnings per Share		 ($0.08) $0.23 ($0.02) $0.04 $0.09 ($8.65) $0.14 ($1.66) ($0.03) ($0.02) $0.11
Weighted Average Basic Shares Outstanding		 46.43M 46.20M 45.90M 45.95M 45.96M 46.00M 46.24M 46.40M 46.42M 46.50M 46.82M
Diluted Earnings per Share		 ($0.08) $0.23 ($0.02) $0.04 $0.09 ($8.64) $0.14 ($1.66) ($0.03) ($0.02) $0.11
Weighted Average Diluted Shares Outstanding		 46.43M 46.20M 45.90M 45.95M 45.96M 46.00M 46.24M 46.40M 46.42M 46.50M 46.82M
Weighted Average Basic & Diluted Shares Outstanding		 46.43M 46.20M 45.90M 45.95M 45.96M 46.00M 46.24M 46.40M 46.42M 46.50M 46.82M

Annual Cash Flow Statements for Avanos Medical

This table details how cash moves in and out of Avanos Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -20 -16 106 170 -179 -94 7.00 9.20 -40 20 -18
Net Cash From Operating Activities		 98 189 144 -146 -75 -2.50 87 91 32 101 75
Net Cash From Continuing Operating Activities		 98 189 144 -146 -75 -2.50 87 91 32 101 75
Net Income / (Loss) Continuing Operations		 -426 40 79 58 -46 -29 6.30 51 -62 -392 -73
Consolidated Net Income / (Loss)		 -426 40 79 58 -46 -29 6.30 51 -62 -392 -73
Depreciation Expense		 65 65 60 34 37 43 38 48 46 46 39
Non-Cash Adjustments To Reconcile Net Income		 481 19 16 -86 11 36 21 17 89 452 99
Changes in Operating Assets and Liabilities, net		 -23 65 -11 -150 -77 -52 22 -24 -40 -4.40 9.80
Net Cash From Investing Activities		 -63 -201 -43 640 -108 -24 -21 -135 22 -28 -61
Net Cash From Continuing Investing Activities		 -63 -201 -43 640 -108 -24 -21 -135 22 -28 -61
Purchase of Property, Plant & Equipment		 -70 -29 -43 -49 -51 -20 -21 -19 -18 -18 -32
Acquisitions		 0.00 -175 0.00 -66 -58 0.00 0.00 -116 -50 0.00 -28
Sale of Property, Plant & Equipment		 7.80 3.20 0.10 - - - - - 0.00 0.00 4.00
Divestitures		 - 0.00 0.00 754 - - 0.00 0.00 89 2.10 0.00
Other Investing Activities, net		 - - - - - - - 0.00 - - -5.00
Net Cash From Financing Activities		 -51 -1.40 2.20 -324 1.50 -70 -55 57 -94 -49 -37
Net Cash From Continuing Financing Activities		 -51 -1.40 2.20 -324 1.50 -70 -55 57 -94 -49 -37
Repayment of Debt		 -51 -73 0.00 -341 -0.20 -255 -50 -300 -120 -54 -34
Repurchase of Common Equity		 -1.00 -0.90 -2.50 -0.90 -3.60 -0.90 -12 -46 -19 -13 -3.30
Issuance of Debt		 - 72 - 0.00 0.00 185 0.00 400 55 20 0.00
Other Financing Activities, net		 1.40 0.40 4.70 17 5.30 0.70 6.20 1.70 -10 -2.70 0.70
Effect of Exchange Rate Changes		 -3.90 -2.30 - - 1.90 - -4.00 -3.00 0.20 - 5.00
Cash Interest Paid		 33 30 29 21 17 17 3.00 8.10 15 12 6.50
Cash Income Taxes Paid		 43 29 21 97 8.40 - 45 2.90 -24 -3.30 -14

Quarterly Cash Flow Statements for Avanos Medical

This table details how cash moves in and out of Avanos Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 25 -19 -12 16 -3.20 19 -11 -6.70 -20 19 -24
Net Cash From Operating Activities		 29 13 -8.00 28 23 58 26 6.80 14 28 -12
Net Cash From Continuing Operating Activities		 29 13 -8.00 28 23 58 26 6.80 14 28 -12
Net Income / (Loss) Continuing Operations		 -3.70 11 -0.90 1.80 4.30 -397 6.60 -77 -1.40 -1.30 5.10
Consolidated Net Income / (Loss)		 -3.70 11 -0.90 1.80 4.30 -397 6.60 -77 -1.40 -1.30 5.10
Depreciation Expense		 11 12 11 11 12 11 9.60 10 9.40 9.90 10
Non-Cash Adjustments To Reconcile Net Income		 5.00 17 3.90 3.80 2.70 441 4.00 81 8.90 4.80 3.80
Changes in Operating Assets and Liabilities, net		 17 -26 -22 11 4.30 2.80 5.50 -7.60 -2.90 15 -31
Net Cash From Investing Activities		 -49 81 -2.00 -5.90 -12 -7.60 -9.10 -13 -32 -6.80 -7.70
Net Cash From Continuing Investing Activities		 -49 81 -2.00 -5.90 -12 -7.60 -9.10 -13 -32 -6.80 -7.70
Purchase of Property, Plant & Equipment		 -3.90 -5.90 -4.10 -5.90 -3.00 -4.80 -6.70 -11 -7.00 -6.90 -4.30
Acquisitions		 -45 -2.10 - - - - -2.40 - - 0.30 -3.40
Net Cash From Financing Activities		 47 -115 -0.70 -5.00 -16 -27 -29 -3.20 -2.00 -2.70 -3.20
Net Cash From Continuing Financing Activities		 47 -115 -0.70 -5.00 -16 -27 -29 -3.20 -2.00 -2.70 -3.20
Repayment of Debt		 - -97 -12 -1.50 -13 -27 -27 -2.40 -2.30 -2.40 -2.30
Repurchase of Common Equity		 -9.20 -6.20 -9.10 -3.50 -0.10 -0.10 -2.20 -0.80 - -0.30 -1.30
Other Financing Activities, net		 0.90 -12 0.00 - -2.70 - 0.40 - 0.30 - 0.40
Other Net Changes in Cash		 - - - - - - - - - - -1.00

Annual Balance Sheets for Avanos Medical

This table presents Avanos Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2,000 2,072 2,196 1,833 1,800 1,673 1,604 1,787 1,692 1,154 1,074
Total Current Assets		 676 594 1,161 714 539 467 428 624 487 393 355
Cash & Equivalents		 130 114 220 385 205 112 119 128 88 108 90
Accounts Receivable		 225 189 203 151 152 109 131 168 143 133 104
Inventories, net		 303 81 91 121 146 169 159 132 163 139 148
Prepaid Expenses		 19 17 14 57 24 19 19 14 29 14 14
Plant, Property, & Equipment, net		 280 109 110 154 185 175 168 119 117 111 113
Total Noncurrent Assets		 1,045 1,369 925 966 1,077 1,030 1,008 1,044 1,088 650 605
Goodwill		 945 762 765 784 801 803 802 760 796 456 395
Intangible Assets		 83 168 149 168 184 158 141 234 240 112 118
Noncurrent Deferred & Refundable Income Taxes		 15 8.60 7.60 6.30 16 10 10 4.60 6.50 25 33
Other Noncurrent Operating Assets		 2.00 3.00 4.10 7.60 75 60 55 45 46 57 59
Total Liabilities & Shareholders' Equity		 2,000 2,072 2,196 1,833 1,800 1,673 1,604 1,787 1,692 1,154 1,074
Total Liabilities		 945 969 981 536 534 416 333 496 456 326 296
Total Current Liabilities		 315 324 390 264 213 166 139 191 235 166 165
Short-Term Debt		 - 0.00 40 - - - 0.00 6.20 8.60 9.40 10
Accounts Payable		 163 161 171 170 83 68 56 68 56 54 56
Accrued Expenses		 152 138 145 94 115 83 68 98 93 91 91
Other Current Liabilities		 - - - - 15 16 15 12 13 11 8.20
Total Noncurrent Liabilities		 630 645 591 272 322 250 194 305 222 160 130
Long-Term Debt		 578 579 541 248 248 180 130 226 159 125 90
Noncurrent Deferred & Payable Income Tax Liabilities		 24 35 18 4.40 0.00 5.70 12 25 24 5.50 6.10
Other Noncurrent Operating Liabilities		 28 24 32 20 74 64 52 53 38 29 34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,055 1,103 1,215 1,297 1,265 1,257 1,271 1,291 1,236 829 778
Total Preferred & Common Equity		 1,055 1,103 1,215 1,297 1,265 1,257 1,271 1,291 1,236 829 778
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,055 1,103 1,215 1,297 1,265 1,257 1,271 1,291 1,236 829 778
Common Stock		 1,519 1,534 1,551 1,579 1,594 1,610 1,629 1,647 1,664 1,679 1,692
Retained Earnings		 -419 -379 -300 -242 -288 -316 -304 -253 -315 -707 -780
Accumulated Other Comprehensive Income / (Loss)		 -43 -50 -31 -34 -32 -28 -34 -36 -27 -45 -32
Other Equity Adjustments		 - - - - - - -21 -67 -86 -99 -102

Quarterly Balance Sheets for Avanos Medical

This table presents Avanos Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,775 1,735 1,667 1,725 1,661 1,658 1,656 1,108 1,039 1,068 1,050
Total Current Assets		 470 454 507 525 468 474 473 352 356 351 325
Cash & Equivalents		 117 96 82 107 76 92 89 97 90 71 66
Accounts Receivable		 146 143 152 145 131 123 132 105 110 112 103
Inventories, net		 194 200 148 157 166 164 162 138 143 151 141
Prepaid Expenses		 13 15 16 14 29 22 16 13 13 19 15
Plant, Property, & Equipment, net		 163 164 123 117 116 111 110 110 114 115 111
Total Noncurrent Assets		 1,142 1,118 1,037 1,084 1,077 1,073 1,074 646 569 601 614
Goodwill		 824 822 763 792 795 794 795 456 381 394 394
Intangible Assets		 259 245 223 242 233 226 220 107 105 122 115
Noncurrent Deferred & Refundable Income Taxes		 11 4.50 4.40 4.30 6.30 6.30 6.60 25 25 25 33
Other Noncurrent Operating Assets		 49 47 48 46 43 46 52 58 57 59 72
Total Liabilities & Shareholders' Equity		 1,775 1,735 1,667 1,725 1,661 1,658 1,656 1,108 1,039 1,068 1,050
Total Liabilities		 512 436 432 503 433 436 427 268 263 290 268
Total Current Liabilities		 162 159 161 171 205 208 213 137 135 148 131
Short-Term Debt		 6.20 6.20 6.20 6.20 9.40 10 9.40 9.40 9.40 9.40 11
Accounts Payable		 63 60 65 52 57 51 54 46 49 54 52
Accrued Expenses		 80 81 73 97 75 80 83 71 66 75 58
Other Current Liabilities		 13 12 14 13 12 14 14 10 10 9.50 10
Total Noncurrent Liabilities		 349 278 271 332 228 228 214 131 128 142 137
Long-Term Debt		 248 205 203 258 167 165 153 98 96 93 87
Noncurrent Deferred & Payable Income Tax Liabilities		 37 25 22 29 24 23 24 5.60 6.30 6.30 5.60
Other Noncurrent Operating Liabilities		 65 48 46 45 37 39 37 28 26 42 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,264 1,299 1,235 1,222 1,228 1,222 1,230 839 776 778 782
Total Preferred & Common Equity		 1,264 1,299 1,235 1,222 1,228 1,222 1,230 839 776 778 782
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,264 1,299 1,235 1,222 1,228 1,222 1,230 839 776 778 782
Common Stock		 1,643 1,652 1,655 1,660 1,668 1,672 1,675 1,683 1,687 1,691 1,697
Retained Earnings		 -270 -254 -322 -325 -316 -314 -310 -700 -777 -779 -775
Accumulated Other Comprehensive Income / (Loss)		 -43 -31 -28 -33 -30 -38 -37 -42 -32 -33 -36
Other Equity Adjustments		 - -68 -71 -80 -95 -99 -99 -101 -102 -102 -104

Annual Metrics And Ratios for Avanos Medical

This table displays calculated financial ratios and metrics derived from Avanos Medical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -69.56% 11.24% 8.02% 6.65% 6.94% 2.47% -17.88% 16.54% -1.58% 2.15% 1.95%
EBITDA Growth		 -139.12% 40.40% 139.14% 107.32% -155.29% 70.21% 87.50% 11,985.71% -39.54% -797.22% 93.53%
EBIT Growth		 -243.90% 21.08% 59.76% 101.16% -11,240.00% 12.93% 19.59% 191.03% -88.17% -9,533.33% 84.45%
NOPAT Growth		 -438.99% 21.08% 59.76% 101.16% -11,240.00% 12.93% 19.59% 204.71% -89.72% -9,533.33% 84.45%
Net Income Growth		 -1,673.06% 109.34% 99.25% -27.49% -179.83% 36.82% 121.72% 701.59% -222.38% -534.47% 81.41%
EPS Growth		 -1,677.59% 109.29% 98.82% -27.81% -178.69% 36.46% 121.31% 723.08% -223.36% -546.21% 81.59%
Operating Cash Flow Growth		 -34.01% 93.44% -23.62% -200.97% 48.83% 96.64% 3,592.00% 4.12% -64.36% 210.80% -25.82%
Free Cash Flow Firm Growth		 122.62% 16.14% -106.48% -524.10% -2.49% 72.69% 130.62% 476.19% -202.42% 298.74% -87.17%
Invested Capital Growth		 -24.29% -34.90% -0.10% 18.65% 12.72% 1.30% -3.24% -4.78% 7.78% -34.98% -7.78%
Revenue Q/Q Growth		 -68.43% 9.24% 458.08% 0.56% 2.94% -0.67% -20.27% 18.68% 4.63% 0.92% 0.19%
EBITDA Q/Q Growth		 76.71% -110.49% 110.68% -17.68% 28.24% -114.40% 97.07% 58.17% 11.78% -541.69% 94.87%
EBIT Q/Q Growth		 63.74% -132.06% 80.30% -91.38% 8.39% -977.78% 38.58% 303.41% 240.00% -1,282.69% 87.24%
NOPAT Q/Q Growth		 63.74% -118.34% 80.30% -91.38% 8.39% -977.78% 38.58% 210.58% 240.00% -1,095.75% 87.24%
Net Income Q/Q Growth		 3.81% -10.16% 40.35% -37.84% -9.29% -308.63% 111.67% 12.47% -11.55% -2,597.45% 84.45%
EPS Q/Q Growth		 3.89% -10.53% 39.67% -37.44% -10.34% -303.33% 111.40% 13.83% -11.86% -2,608.82% 84.59%
Operating Cash Flow Q/Q Growth		 -15.28% 13.12% 15.36% -96.49% 5.70% 61.54% 140.50% -16.83% -39.33% 81.44% -28.45%
Free Cash Flow Firm Q/Q Growth		 0.00% 55.69% 74.40% -139.31% 9.84% 16.68% 221.65% 176.66% -177.69% 602.27% -82.42%
Invested Capital Q/Q Growth		 -0.69% -40.09% -38.68% 2.15% 0.58% -2.46% -2.06% -12.83% 2.80% -33.25% -2.64%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 50.65% 52.49% 55.09% 59.93% 57.65% 51.89% 50.97% 57.62% 56.39% 55.44% 50.47%
EBITDA Margin		 -13.81% -7.40% 2.68% 5.21% -2.70% -0.78% -0.12% 12.16% 7.47% -50.99% -3.24%
Operating Margin		 -26.66% -18.92% -7.05% 0.08% -7.98% -6.79% -6.64% 5.19% 0.62% -57.60% -8.78%
EBIT Margin		 -26.66% -18.92% -7.05% 0.08% -7.98% -6.79% -6.64% 5.19% 0.62% -57.60% -8.78%
Profit (Net Income) Margin		 -83.75% 7.03% 12.97% 8.82% -6.58% -4.06% 1.07% 7.38% -9.18% -57.01% -10.40%
Tax Burden Percent		 253.00% -28.59% -109.83% -317.68% 71.72% 46.10% -14.96% 189.14% 782.28% 97.22% 110.12%
Interest Burden Percent		 124.17% 129.97% 167.52% -3,620.00% 114.90% 129.69% 107.95% 75.21% -188.10% 101.79% 107.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.48% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -5.44% -6.04% -3.08% 0.03% -3.16% -2.58% -2.09% 2.28% 0.23% -25.55% -5.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 -75.66% 64.57% -63.75% -30.51% 11.54% 6.32% 81.91% -72.13% -1,422.63% -241.06% -163.23%
Return on Net Nonoperating Assets (RNNOA)		 -28.04% 9.73% 9.93% 4.54% -0.42% 0.28% 2.59% 1.66% -5.12% -12.43% -3.83%
Return on Equity (ROE)		 -33.48% 3.69% 6.84% 4.58% -3.58% -2.30% 0.50% 3.94% -4.89% -37.98% -9.07%
Cash Return on Invested Capital (CROIC)		 22.20% 36.24% -2.98% -17.03% -15.12% -3.87% 1.20% 7.18% -7.26% 16.85% 2.86%
Operating Return on Assets (OROA)		 -6.01% -5.26% -2.02% 0.02% -3.07% -2.79% -2.38% 2.09% 0.24% -27.84% -5.53%
Return on Assets (ROA)		 -18.87% 1.95% 3.72% 2.85% -2.53% -1.67% 0.38% 2.98% -3.55% -27.55% -6.54%
Return on Common Equity (ROCE)		 -33.48% 3.69% 6.84% 4.58% -3.58% -2.30% 0.50% 3.94% -4.89% -37.98% -9.07%
Return on Equity Simple (ROE_SIMPLE)		 -40.40% 3.61% 6.52% 4.43% -3.63% -2.31% 0.50% 3.91% -5.00% -47.33% 0.00%
Net Operating Profit after Tax (NOPAT)		 -95 -75 -30 0.35 -39 -34 -27 29 2.94 -277 -43
NOPAT Margin		 -18.66% -13.24% -4.93% 0.05% -5.59% -4.75% -4.65% 4.18% 0.44% -40.32% -6.15%
Net Nonoperating Expense Percent (NNEP)		 70.22% -70.61% 60.67% 30.55% -14.70% -8.89% -84.00% 74.41% 1,422.86% 215.51% 157.98%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 1.88% 0.21% -28.79% -4.91%
Cost of Revenue to Revenue		 49.35% 47.51% 44.92% 40.07% 42.35% 48.11% 49.03% 42.38% 43.61% 44.56% 49.53%
SG&A Expenses to Revenue		 68.70% 61.14% 52.60% 52.18% 57.21% 46.53% 48.60% 47.73% 49.75% 46.31% 45.01%
R&D to Revenue		 5.42% 6.78% 6.25% 6.41% 5.40% 4.88% 5.21% 4.27% 4.04% 3.81% 3.32%
Operating Expenses to Revenue		 77.31% 71.41% 62.13% 59.85% 65.64% 58.67% 57.62% 52.43% 55.77% 113.04% 59.26%
Earnings before Interest and Taxes (EBIT)		 -136 -107 -43 0.50 -56 -49 -39 36 4.20 -396 -62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -70 -42 16 34 -19 -5.60 -0.70 83 50 -351 -23
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.48 1.57 1.78 1.64 1.28 1.75 1.31 0.97 0.84 0.88 0.67
Price to Tangible Book Value (P/TBV)		 56.63 10.03 7.17 6.15 5.77 7.41 5.10 4.24 5.19 2.81 1.96
Price to Revenue (P/Rev)		 3.06 3.05 3.54 3.26 2.32 3.07 2.85 1.84 1.55 1.06 0.74
Price to Earnings (P/E)		 0.00 43.37 27.28 36.94 0.00 0.00 265.18 24.92 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 2.31% 3.67% 2.71% 0.00% 0.00% 0.38% 4.01% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.33 2.24 2.58 1.71 1.27 1.71 1.31 1.12 0.85 0.89 0.67
Enterprise Value to Revenue (EV/Rev)		 3.94 3.87 4.13 3.05 2.38 3.17 2.87 1.99 1.67 1.10 0.76
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 153.91 58.46 0.00 0.00 0.00 16.38 22.30 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 3,975.04 0.00 0.00 0.00 38.40 267.05 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 5,678.63 0.00 0.00 0.00 47.68 381.51 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 20.55 11.61 17.50 0.00 0.00 0.00 19.27 14.99 34.62 7.53 7.12
Enterprise Value to Free Cash Flow (EV/FCFF)		 5.18 4.87 0.00 0.00 0.00 0.00 107.83 15.16 0.00 4.15 22.66
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.55 0.53 0.48 0.19 0.20 0.14 0.10 0.18 0.14 0.16 0.13
Long-Term Debt to Equity		 0.55 0.53 0.45 0.19 0.20 0.14 0.10 0.18 0.13 0.15 0.12
Financial Leverage		 0.37 0.15 -0.16 -0.15 -0.04 0.04 0.03 -0.02 0.00 0.05 0.02
Leverage Ratio		 1.77 1.89 1.84 1.60 1.42 1.38 1.30 1.32 1.38 1.38 1.39
Compound Leverage Factor		 2.20 2.45 3.08 -58.05 1.63 1.79 1.40 1.00 -2.59 1.40 1.49
Debt to Total Capital		 35.39% 34.43% 32.34% 16.03% 16.39% 12.53% 9.28% 15.26% 11.96% 13.98% 11.44%
Short-Term Debt to Total Capital		 0.00% 0.00% 2.22% 0.00% 0.00% 0.00% 0.00% 0.41% 0.61% 0.98% 1.16%
Long-Term Debt to Total Capital		 35.39% 34.43% 30.12% 16.03% 16.39% 12.53% 9.28% 14.85% 11.35% 13.01% 10.28%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 64.61% 65.57% 67.66% 83.97% 83.61% 87.47% 90.72% 84.74% 88.04% 86.02% 88.56%
Debt to EBITDA		 -8.22 -13.82 35.42 7.29 -13.20 -32.14 -185.71 2.79 3.34 -0.38 -4.43
Net Debt to EBITDA		 -6.38 -11.11 22.02 -4.02 -2.28 -12.23 -16.43 1.26 1.60 -0.08 -0.47
Long-Term Debt to EBITDA		 -8.22 -13.82 32.99 7.29 -13.20 -32.14 -185.71 2.72 3.17 -0.36 -3.98
Debt to NOPAT		 -6.09 -7.72 -19.25 707.71 -6.36 -5.30 -4.76 8.13 57.14 -0.49 -2.33
Net Debt to NOPAT		 -4.72 -6.21 -11.97 -390.86 -1.10 -2.02 -0.42 3.67 27.31 -0.10 -0.25
Long-Term Debt to NOPAT		 -6.09 -7.72 -17.94 707.71 -6.36 -5.30 -4.76 7.92 54.22 -0.45 -2.09
Altman Z-Score		 0.94 1.07 1.77 2.84 2.09 3.45 3.25 2.06 1.69 0.19 0.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.14 1.83 2.98 2.70 2.53 2.81 3.07 3.27 2.08 2.37 2.15
Quick Ratio		 1.12 0.93 1.08 2.02 1.68 1.32 1.79 1.55 0.98 1.45 1.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 387 450 -29 -182 -187 -51 16 90 -92 183 23
Operating Cash Flow to CapEx		 155.91% 728.96% 334.57% -296.54% -147.23% -12.38% 415.71% 470.98% 182.02% 565.73% 270.65%
Free Cash Flow to Firm to Interest Expense		 11.70 13.76 -0.92 -6.90 -12.44 -3.27 4.73 8.99 -6.14 15.00 3.01
Operating Cash Flow to Interest Expense		 2.95 5.77 4.56 -5.52 -4.97 -0.16 26.45 9.09 2.16 8.25 9.58
Operating Cash Flow Less CapEx to Interest Expense		 1.06 4.98 3.20 -7.38 -8.34 -1.46 20.09 7.16 0.97 6.80 6.04
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.23 0.28 0.29 0.32 0.38 0.41 0.36 0.40 0.39 0.48 0.63
Accounts Receivable Turnover		 2.22 2.74 3.12 3.69 4.61 5.48 4.90 4.57 4.33 4.99 5.93
Inventory Turnover		 0.86 1.40 3.20 2.46 2.21 2.18 1.75 1.99 1.99 2.03 2.42
Fixed Asset Turnover		 1.83 2.91 5.58 4.94 4.12 3.97 3.42 4.77 5.71 6.04 6.26
Accounts Payable Turnover		 1.51 1.66 1.66 1.53 2.34 4.57 4.64 4.66 4.73 5.54 6.33
Days Sales Outstanding (DSO)		 164.43 133.18 116.82 98.90 79.24 66.64 74.55 79.79 84.22 73.13 61.58
Days Inventory Outstanding (DIO)		 425.95 260.45 114.14 148.36 165.14 167.06 208.12 183.57 183.68 179.82 150.71
Days Payable Outstanding (DPO)		 241.13 219.68 220.44 238.14 156.24 79.92 78.63 78.25 77.20 65.85 57.70
Cash Conversion Cycle (CCC)		 349.25 173.96 10.52 9.12 88.14 153.77 204.04 185.11 190.70 187.09 154.59
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,504 979 978 1,160 1,308 1,325 1,282 1,221 1,316 856 789
Invested Capital Turnover		 0.29 0.46 0.63 0.61 0.57 0.54 0.45 0.55 0.53 0.63 0.85
Increase / (Decrease) in Invested Capital		 -482 -525 -1.00 182 148 17 -43 -61 95 -460 -67
Enterprise Value (EV)		 2,006 2,191 2,524 1,988 1,658 2,263 1,682 1,363 1,122 759 532
Market Capitalization		 1,557 1,726 2,163 2,124 1,615 2,195 1,671 1,258 1,041 732 521
Book Value per Share		 $22.64 $23.62 $25.95 $27.35 $26.40 $26.27 $26.37 $27.77 $26.63 $18.03 $16.76
Tangible Book Value per Share		 $0.59 $3.69 $6.44 $7.28 $5.84 $6.19 $6.80 $6.38 $4.32 $5.67 $5.72
Total Capital		 1,633 1,682 1,796 1,545 1,513 1,437 1,401 1,524 1,404 963 879
Total Debt		 578 579 581 248 248 180 130 233 168 135 101
Total Long-Term Debt		 578 579 541 248 248 180 130 226 159 125 90
Net Debt		 449 465 361 -137 43 69 12 105 80 27 11
Capital Expenditures (CapEx)		 63 26 43 49 51 20 21 19 18 18 28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 231 155 591 65 121 189 170 312 173 129 111
Debt-free Net Working Capital (DFNWC)		 361 269 811 449 326 301 288 439 261 237 200
Net Working Capital (NWC)		 361 269 771 449 326 301 288 433 252 228 190
Net Nonoperating Expense (NNE)		 331 -115 -109 -57 6.91 -4.95 -34 -22 65 115 30
Net Nonoperating Obligations (NNO)		 449 -124 -237 -137 43 69 12 -70 80 27 11
Total Depreciation and Amortization (D&A)		 65 65 60 34 37 43 38 48 46 46 39
Debt-free, Cash-free Net Working Capital to Revenue		 45.44% 27.45% 96.63% 9.93% 17.30% 26.50% 28.94% 45.55% 25.74% 18.78% 15.77%
Debt-free Net Working Capital to Revenue		 70.88% 47.53% 132.55% 68.88% 46.73% 42.10% 49.13% 64.22% 38.76% 34.44% 28.58%
Net Working Capital to Revenue		 70.88% 47.53% 126.05% 68.88% 46.73% 42.10% 49.13% 63.31% 37.49% 33.08% 27.12%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($9.15) $0.85 $1.69 $1.22 ($0.96) ($0.57) $0.11 $1.08 ($1.32) ($8.53) ($1.57)
Adjusted Weighted Average Basic Shares Outstanding		 46.61M 46.68M 46.92M 47.45M 47.76M 47.97M 47.32M 46.60M 46.20M 46.00M 46.50M
Adjusted Diluted Earnings per Share		 ($9.15) $0.85 $1.69 $1.22 ($0.96) ($0.57) $0.11 $1.07 ($1.32) ($8.53) ($1.57)
Adjusted Weighted Average Diluted Shares Outstanding		 46.61M 46.68M 46.92M 47.45M 47.76M 47.97M 47.32M 46.60M 46.20M 46.00M 46.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.61M 46.68M 46.92M 47.45M 47.76M 47.97M 47.32M 46.60M 46.20M 46.00M 46.50M
Normalized Net Operating Profit after Tax (NOPAT)		 -95 -75 -30 0.35 -39 -34 -27 29 2.94 28 11
Normalized NOPAT Margin		 -18.66% -13.24% -4.93% 0.05% -5.59% -4.75% -4.65% 4.18% 0.44% 4.12% 1.54%
Pre Tax Income Margin		 -33.10% -24.59% -11.81% -2.77% -9.17% -8.80% -7.17% 3.90% -1.17% -58.64% -9.44%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.10 -3.28 -1.36 0.02 -3.71 -3.11 -11.82 3.55 0.28 -32.48 -7.90
NOPAT to Interest Expense		 -2.87 -2.29 -0.95 0.01 -2.60 -2.18 -8.27 2.86 0.20 -22.73 -5.53
EBIT Less CapEx to Interest Expense		 -5.99 -4.07 -2.73 -1.84 -7.09 -4.40 -18.18 1.62 -0.91 -33.93 -11.44
NOPAT Less CapEx to Interest Expense		 -4.76 -3.08 -2.32 -1.85 -5.97 -3.47 -14.64 0.93 -0.99 -24.19 -9.07
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.23% 2.26% 3.15% 1.57% -7.84% -3.10% 182.54% 90.10% -30.91% -3.26% -4.53%

Quarterly Metrics And Ratios for Avanos Medical

This table displays calculated financial ratios and metrics derived from Avanos Medical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 46,003,150.00 46,243,980.00 46,402,481.00 - 46,503,458.00
DEI Adjusted Shares Outstanding		 - - - - - - 46,003,150.00 46,243,980.00 46,402,481.00 - 46,503,458.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - 0.14 -1.66 -0.03 - 0.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -0.58% 20.77% 4.27% 1.36% -0.53% 3.64% 0.84% 1.92% 4.34% 0.72% 8.78%
EBITDA Growth		 -50.00% 30.46% 156.67% 87.23% 94.26% -1,894.71% 29.22% -466.48% -59.92% 103.04% -4.02%
EBIT Growth		 -90.63% 180.00% 165.57% 400.00% 900.00% -3,836.61% 157.50% -1,282.54% -99.17% 100.60% -13.59%
NOPAT Growth		 -93.97% 1,861.05% 131.23% 397.24% 787.22% -2,216.28% 425.62% -1,293.54% -99.06% 99.08% -14.78%
Net Income Growth		 -123.57% -37.87% -80.00% 102.64% 216.22% -3,883.81% 833.33% -4,366.67% -132.56% 99.67% -22.73%
EPS Growth		 -124.24% -37.84% -100.00% 102.74% 212.50% -3,856.52% 800.00% -4,250.00% -133.33% 99.77% -21.43%
Operating Cash Flow Growth		 2.46% -62.31% -17.65% 1,169.23% -20.96% 355.91% 421.25% -75.54% -39.13% -51.30% -147.86%
Free Cash Flow Firm Growth		 256.78% -230.89% 971.51% -117.03% -95.35% 306.20% 367.71% 1,937.86% 8,240.72% -61.82% -91.29%
Invested Capital Growth		 -8.61% 7.78% -7.04% 2.26% 0.14% -34.98% -35.35% -38.43% -36.78% -7.78% -4.13%
Revenue Q/Q Growth		 1.12% 1.17% -4.15% 3.37% -0.76% 5.40% -6.74% 4.48% 1.60% 1.74% 0.72%
EBITDA Q/Q Growth		 29.79% 86.07% -32.16% 14.29% 34.66% -1,818.99% 104.88% -424.12% 114.73% 30.53% 54.03%
EBIT Q/Q Growth		 157.14% 833.33% -64.29% 57.50% 90.48% -3,587.50% 102.46% -823.30% 100.13% 2,400.00% 256.00%
NOPAT Q/Q Growth		 157.14% 1,547.94% -90.37% 227.70% 70.57% -4,030.83% 102.39% -844.12% 100.13% -3,969.05% 320.52%
Net Income Q/Q Growth		 94.57% 383.78% -108.57% 300.00% 138.89% -9,339.53% 101.66% -1,263.64% 98.18% 7.14% 492.31%
EPS Q/Q Growth		 94.52% 387.50% -108.70% 300.00% 125.00% -9,700.00% 101.62% -1,285.71% 98.19% 33.33% 650.00%
Operating Cash Flow Q/Q Growth		 1,219.23% -56.36% -162.99% 447.50% -17.27% 151.74% -55.61% -73.54% 105.88% 101.43% -143.62%
Free Cash Flow Firm Q/Q Growth		 -13.95% -166.83% 224.24% -123.83% 123.52% 2,860.57% 181.81% -6.35% 6.75% -86.45% -35.72%
Invested Capital Q/Q Growth		 1.86% 2.80% -0.11% -2.24% -0.25% -33.25% -0.67% -6.91% 2.43% -2.64% 3.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 55.75% 54.82% 57.07% 55.68% 54.52% 54.57% 53.61% 52.63% 48.37% 47.54% 51.70%
EBITDA Margin		 7.12% 13.10% 9.27% 10.25% 13.91% -226.84% 11.88% -36.86% 5.34% 6.85% 10.48%
Operating Margin		 0.70% 6.46% 2.41% 3.67% 7.04% -233.02% 6.15% -42.57% 0.06% 1.38% 4.88%
EBIT Margin		 0.70% 6.46% 2.41% 3.67% 7.04% -233.02% 6.15% -42.57% 0.06% 1.38% 4.88%
Profit (Net Income) Margin		 -2.16% 6.06% -0.54% 1.05% 2.52% -221.21% 3.94% -43.89% -0.79% -0.72% 2.80%
Tax Burden Percent		 142.31% 117.98% -60.00% 29.03% 45.26% 94.48% 68.04% 101.19% 116.67% -108.33% 67.11%
Interest Burden Percent		 -216.67% 79.46% 37.50% 98.41% 79.17% 100.48% 94.17% 101.88% -1,200.00% 48.00% 85.39%
Effective Tax Rate		 0.00% -23.60% 66.67% 30.65% 37.89% 0.00% 31.96% 0.00% 0.00% 208.33% 32.89%
Return on Invested Capital (ROIC)		 0.24% 4.24% 0.40% 1.37% 2.33% -103.34% 2.66% -19.88% 0.03% -1.28% 2.82%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.43% -69.23% -1.81% -4.71% -3.42% -299.30% 1.82% -83.33% -3.46% 6.19% -1.24%
Return on Net Nonoperating Assets (RNNOA)		 -0.35% -0.25% -0.14% -0.16% -0.15% -15.44% 0.09% -3.24% -0.15% 0.15% -0.03%
Return on Equity (ROE)		 -0.11% 3.99% 0.26% 1.20% 2.17% -118.78% 2.75% -23.12% -0.12% -1.13% 2.79%
Cash Return on Invested Capital (CROIC)		 8.84% -7.26% 6.67% -1.34% 2.03% 16.85% 17.71% 15.83% 12.77% 2.86% -1.08%
Operating Return on Assets (OROA)		 0.26% 2.50% 0.96% 1.51% 2.84% -112.60% 3.06% -21.86% 0.03% 0.87% 3.24%
Return on Assets (ROA)		 -0.79% 2.35% -0.22% 0.43% 1.02% -106.90% 1.96% -22.54% -0.40% -0.45% 1.86%
Return on Common Equity (ROCE)		 -0.11% 3.99% 0.26% 1.20% 2.17% -118.78% 2.75% -23.12% -0.12% -1.13% 2.79%
Return on Equity Simple (ROE_SIMPLE)		 -4.53% 0.00% -5.07% 0.63% 1.28% 0.00% -45.82% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.84 14 1.33 4.37 7.45 -293 7.01 -52 0.07 -2.71 5.97
NOPAT Margin		 0.49% 7.99% 0.80% 2.54% 4.37% -163.11% 4.18% -29.80% 0.04% -1.50% 3.28%
Net Nonoperating Expense Percent (NNEP)		 4.66% 73.47% 2.21% 6.07% 5.74% 195.96% 0.84% 63.45% 3.49% -7.47% 4.06%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.99% - - - -30.41% 0.74% -5.92% 0.01% -0.31% 0.68%
Cost of Revenue to Revenue		 44.25% 45.18% 42.93% 44.32% 45.48% 45.43% 46.39% 47.37% 51.63% 52.46% 48.30%
SG&A Expenses to Revenue		 45.94% 42.99% 50.33% 47.12% 43.60% 44.38% 45.19% 47.71% 43.64% 43.56% 42.65%
R&D to Revenue		 3.56% 3.92% 4.21% 3.67% 4.23% 3.17% 3.22% 3.31% 3.37% 3.37% 2.85%
Operating Expenses to Revenue		 55.05% 48.36% 54.67% 52.01% 47.48% 287.58% 47.46% 95.20% 48.31% 46.16% 46.82%
Earnings before Interest and Taxes (EBIT)		 1.20 11 4.00 6.30 12 -419 10 -75 0.10 2.50 8.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 12 23 15 18 24 -407 20 -65 9.50 12 19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.78 0.84 0.75 0.75 0.90 0.88 0.79 0.73 0.69 0.67 0.83
Price to Tangible Book Value (P/TBV)		 5.03 5.19 4.62 4.54 5.15 2.81 2.39 1.95 2.05 1.96 2.38
Price to Revenue (P/Rev)		 1.47 1.55 1.36 1.34 1.62 1.06 0.96 0.82 0.77 0.74 0.91
Price to Earnings (P/E)		 0.00 0.00 0.00 118.75 70.33 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.84% 1.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.86 0.85 0.78 0.78 0.92 0.89 0.79 0.73 0.70 0.67 0.84
Enterprise Value to Revenue (EV/Rev)		 1.72 1.67 1.51 1.46 1.73 1.10 0.97 0.84 0.81 0.76 0.96
Enterprise Value to EBITDA (EV/EBITDA)		 24.56 22.30 17.17 14.69 14.83 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 267.05 71.69 43.93 35.14 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 381.51 0.00 87.87 42.26 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 20.70 34.62 32.86 16.19 21.21 7.53 4.98 5.12 5.45 7.12 18.64
Enterprise Value to Free Cash Flow (EV/FCFF)		 9.33 0.00 11.26 0.00 45.18 4.15 3.49 3.53 4.26 22.66 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.22 0.14 0.14 0.14 0.13 0.16 0.13 0.14 0.13 0.13 0.13
Long-Term Debt to Equity		 0.21 0.13 0.14 0.13 0.12 0.15 0.12 0.12 0.12 0.12 0.11
Financial Leverage		 0.08 0.00 0.08 0.03 0.04 0.05 0.05 0.04 0.04 0.02 0.03
Leverage Ratio		 1.41 1.38 1.34 1.35 1.38 1.38 1.34 1.35 1.36 1.39 1.33
Compound Leverage Factor		 -3.05 1.09 0.50 1.33 1.09 1.39 1.26 1.37 -16.28 0.67 1.14
Debt to Total Capital		 17.79% 11.96% 12.57% 12.53% 11.64% 13.98% 11.34% 11.92% 11.67% 11.44% 11.16%
Short-Term Debt to Total Capital		 0.42% 0.61% 0.67% 0.73% 0.68% 0.98% 0.99% 1.07% 1.07% 1.16% 1.24%
Long-Term Debt to Total Capital		 17.38% 11.35% 11.90% 11.80% 10.97% 13.01% 10.35% 10.86% 10.60% 10.28% 9.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 82.21% 88.04% 87.43% 87.47% 88.36% 86.02% 88.66% 88.08% 88.33% 88.56% 88.84%
Debt to EBITDA		 5.88 3.34 2.96 2.58 2.04 -0.38 -0.31 -0.25 -0.23 -4.43 -4.18
Net Debt to EBITDA		 3.50 1.60 1.69 1.22 0.92 -0.08 -0.03 -0.03 -0.07 -0.47 -1.39
Long-Term Debt to EBITDA		 5.74 3.17 2.80 2.43 1.92 -0.36 -0.28 -0.22 -0.21 -3.98 -3.71
Debt to NOPAT		 -125.95 57.14 -20.84 15.43 5.82 -0.49 -0.39 -0.32 -0.30 -2.33 -2.23
Net Debt to NOPAT		 -74.95 27.31 -11.90 7.30 2.62 -0.10 -0.04 -0.04 -0.10 -0.25 -0.74
Long-Term Debt to NOPAT		 -123.00 54.22 -19.73 14.53 5.48 -0.45 -0.36 -0.29 -0.28 -2.09 -1.98
Altman Z-Score		 1.49 1.71 1.62 1.61 1.92 0.13 1.47 0.93 0.97 0.91 1.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.07 2.08 2.28 2.28 2.22 2.37 2.57 2.64 2.38 2.15 2.48
Quick Ratio		 1.48 0.98 1.01 1.03 1.04 1.45 1.47 1.49 1.23 1.17 1.29
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 121 -81 101 -24 5.65 167 472 442 471 64 41
Operating Cash Flow to CapEx		 746.15% 215.25% -195.12% 471.19% 766.67% 1,206.25% 383.58% 61.82% 200.00% 408.70% -286.05%
Free Cash Flow to Firm to Interest Expense		 25.84 -24.59 32.53 -7.75 1.77 59.77 224.58 220.83 261.93 33.63 27.38
Operating Cash Flow to Interest Expense		 6.19 3.85 -2.58 8.97 7.19 20.68 12.24 3.40 7.78 14.84 -8.20
Operating Cash Flow Less CapEx to Interest Expense		 5.36 2.06 -3.90 7.06 6.25 18.96 9.05 -2.10 3.89 11.21 -11.07
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.37 0.39 0.40 0.41 0.40 0.48 0.50 0.51 0.51 0.63 0.66
Accounts Receivable Turnover		 4.42 4.33 4.96 4.96 4.92 4.99 5.84 5.94 5.75 5.93 6.89
Inventory Turnover		 1.56 1.99 1.62 1.93 1.90 2.03 2.06 2.09 2.14 2.42 2.56
Fixed Asset Turnover		 4.59 5.71 4.86 5.85 6.02 6.04 6.10 6.16 6.22 6.26 6.48
Accounts Payable Turnover		 4.76 4.73 5.09 5.16 5.70 5.54 6.08 6.38 6.16 6.33 7.28
Days Sales Outstanding (DSO)		 82.64 84.22 73.53 73.63 74.21 73.13 62.52 61.46 63.47 61.58 52.97
Days Inventory Outstanding (DIO)		 234.11 183.68 224.65 188.98 191.71 179.82 177.13 175.02 170.75 150.71 142.59
Days Payable Outstanding (DPO)		 76.74 77.20 71.65 70.70 63.98 65.85 60.08 57.20 59.23 57.70 50.17
Cash Conversion Cycle (CCC)		 240.01 190.70 226.53 191.90 201.93 187.09 179.58 179.28 174.99 154.59 145.40
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,280 1,316 1,314 1,285 1,282 856 850 791 810 789 815
Invested Capital Turnover		 0.48 0.53 0.50 0.54 0.53 0.63 0.64 0.67 0.67 0.85 0.86
Increase / (Decrease) in Invested Capital		 -121 95 -100 28 1.80 -460 -465 -494 -471 -67 -35
Enterprise Value (EV)		 1,105 1,122 1,025 997 1,177 759 670 581 569 532 684
Market Capitalization		 948 1,041 924 914 1,104 732 659 566 536 521 652
Book Value per Share		 $26.07 $26.63 $26.75 $26.62 $26.76 $18.03 $18.25 $16.79 $16.77 $16.76 $16.82
Tangible Book Value per Share		 $4.02 $4.32 $4.36 $4.39 $4.67 $5.67 $6.01 $6.26 $5.64 $5.72 $5.88
Total Capital		 1,487 1,404 1,405 1,397 1,392 963 947 881 881 879 880
Total Debt		 265 168 177 175 162 135 107 105 103 101 98
Total Long-Term Debt		 258 159 167 165 153 125 98 96 93 90 87
Net Debt		 157 80 101 83 73 27 10 15 32 11 33
Capital Expenditures (CapEx)		 3.90 5.90 4.10 5.90 3.00 4.80 6.70 11 7.00 6.90 4.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 253 173 196 184 180 129 128 141 142 111 139
Debt-free Net Working Capital (DFNWC)		 360 261 272 276 269 237 225 231 213 200 205
Net Working Capital (NWC)		 354 252 263 266 260 228 215 221 204 190 194
Net Nonoperating Expense (NNE)		 4.54 3.34 2.23 2.57 3.15 104 0.41 25 1.47 -1.41 0.87
Net Nonoperating Obligations (NNO)		 58 80 87 63 52 27 10 15 32 11 33
Total Depreciation and Amortization (D&A)		 11 12 11 11 12 11 9.60 10 9.40 9.90 10
Debt-free, Cash-free Net Working Capital to Revenue		 39.32% 25.74% 28.85% 26.95% 26.43% 18.78% 18.51% 20.29% 20.35% 15.77% 19.43%
Debt-free Net Working Capital to Revenue		 55.96% 38.76% 39.99% 40.46% 39.49% 34.44% 32.59% 33.33% 30.42% 28.58% 28.59%
Net Working Capital to Revenue		 55.00% 37.49% 38.61% 38.97% 38.11% 33.08% 31.22% 31.97% 29.08% 27.12% 27.07%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.08) $0.23 ($0.02) $0.04 $0.10 ($8.65) $0.14 ($1.66) ($0.03) ($0.02) $0.11
Adjusted Weighted Average Basic Shares Outstanding		 46.43M 46.20M 45.90M 45.95M 45.96M 46.00M 46.24M 46.40M 46.42M 46.50M 46.82M
Adjusted Diluted Earnings per Share		 ($0.08) $0.23 ($0.02) $0.04 $0.09 ($8.64) $0.14 ($1.66) ($0.03) ($0.02) $0.11
Adjusted Weighted Average Diluted Shares Outstanding		 46.43M 46.20M 45.90M 45.95M 45.96M 46.00M 46.24M 46.40M 46.42M 46.50M 46.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.43M 46.20M 45.90M 45.95M 45.96M 46.00M 46.24M 46.40M 46.42M 46.50M 46.82M
Normalized Net Operating Profit after Tax (NOPAT)		 0.84 7.84 2.80 4.37 7.45 -293 7.01 1.75 0.07 1.75 5.97
Normalized NOPAT Margin		 0.49% 4.52% 1.69% 2.54% 4.37% -163.11% 4.18% 1.00% 0.04% 0.97% 3.28%
Pre Tax Income Margin		 -1.52% 5.14% 0.90% 3.61% 5.58% -234.13% 5.79% -43.37% -0.67% 0.66% 4.17%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.26 3.39 1.29 2.03 3.75 -149.46 4.90 -37.25 0.06 1.32 5.93
NOPAT to Interest Expense		 0.18 4.19 0.43 1.41 2.33 -104.63 3.34 -26.08 0.04 -1.43 3.98
EBIT Less CapEx to Interest Expense		 -0.57 1.61 -0.03 0.13 2.81 -151.18 1.71 -42.75 -3.83 -2.32 3.07
NOPAT Less CapEx to Interest Expense		 -0.65 2.41 -0.89 -0.49 1.39 -106.34 0.15 -31.58 -3.85 -5.06 1.11
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -24.01% -30.91% -43.57% 363.64% 120.38% -3.26% -1.53% -0.69% -0.66% -4.53% -3.23%

Financials Breakdown Chart

Key Financial Trends

Avanos Medical (AVNS) has shown a modest 2025 rebound in top-line activity with improving cash flow, while lingering profitability challenges are tied to a sizable one-off impairment in Q2 and ongoing net losses in later quarters. Below are the key trends drawn from Avanos’ quarterly statements over the last four years, focusing on what may matter most to retail investors.

  • 2025 revenue trend: Operating revenue rose from 167.5M (Q1) to 175.0M (Q2), then to 177.8M (Q3) and 180.9M (Q4), signaling a gradual recovery in topline performance.
  • Cash flow from operations: Net cash from continuing operating activities stayed positive through 2025, with Q4 at 28.2M and earlier quarters showing meaningful positive flow (Q1 25.7M, Q2 6.8M, Q3 14.0M).
  • Operating profitability in Q4 2025: Total Operating Income was 2.5M, indicating some operating profitability even as net income remained negative.
  • Debt trend improving: Long-Term Debt declined from 98.0M (Q1 2025) to 93.4M (Q3 2025), suggesting improved leverage through 2025.
  • Gross margin pressure vs. 2024: Gross margin weakened in 2025 (Q4 gross profit of 86.0M on 180.9M revenue, ~47.6% margin) versus 2024 levels that were generally higher, indicating margin compression if revenue growth falters.
  • Cost structure relatively stable: Selling, General & Admin plus Research & Development expenses remained broadly flat in 2025, implying limited near-term operating leverage from cost cuts or savings.
  • Liquidity shows quarterly volatility: Cash & Equivalents declined from 97.0M (Q1 2025) to 90.3M (Q2 2025) to 70.5M (Q3 2025), highlighting liquidity sensitivity to quarterly cash flows.
  • Significant impairment in Q2 2025: An impairment charge of 77.0M weighed heavily on the quarter, contributing to a large net loss despite positive operating cash flow.
  • Net income remains negative in 2025: Net income attributable to common shareholders was markedly negative in Q2 (approximately -76.8M) and remained negative in Q3 and Q4 2025 (around -1.4M and -1.3M respectively), signaling ongoing profitability pressures.
  • Sustained cash outflows from investing/financing in parts of 2025: Several quarters show negative net cash from investing and financing activities (e.g., Q3 2025 and Q2 2025), illustrating continued cash outflows outside core operations even as operating cash improved.
05/22/26 02:32 AM ETAI Generated. May Contain Errors.

Avanos Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Avanos Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Avanos Medical's net income appears to be on an upward trend, with a most recent value of -$72.90 million in 2025, falling from -$426.30 million in 2015. The previous period was -$392.10 million in 2024. View Avanos Medical's forecast to see where analysts expect Avanos Medical to go next.

Avanos Medical's total operating income in 2025 was -$61.60 million, based on the following breakdown:
  • Total Gross Profit: $353.90 million
  • Total Operating Expenses: $415.50 million

Over the last 10 years, Avanos Medical's total revenue changed from $509 million in 2015 to $701.20 million in 2025, a change of 37.8%.

Avanos Medical's total liabilities were at $295.50 million at the end of 2025, a 9.3% decrease from 2024, and a 68.7% decrease since 2015.

In the past 10 years, Avanos Medical's cash and equivalents has ranged from $87.70 million in 2023 to $384.50 million in 2018, and is currently $89.80 million as of their latest financial filing in 2025.

Over the last 10 years, Avanos Medical's book value per share changed from 22.64 in 2015 to 16.76 in 2025, a change of -25.9%.


Related Companies

Financial statements for NYSE:AVNS last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
System failure: The strongest leverage for gold…
$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...
Golden Portfolio | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
I had never heard of this 1888 account
An investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...
The Oxford Club | Sponsoredtc pixel
SpaceX controls two-thirds of all satellites - and it is about to go public
SpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...
NXT Wave Research | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
How to Profit from Elon’s AI lab before it goes public
Elon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...
InvestorPlace | Sponsoredtc pixel
Sneak Peek: Wall Street’s Little Black Book
Tom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what ...
DTI Trader | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel